Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28153746 | 1.00 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL7286305 | 0.95 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL895773 | 0.95 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL19414808 | 0.95 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL2898129 | 0.90 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL2737884 | 0.90 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL88684 | 0.90 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL13804123 | 0.90 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL12427648 | 0.90 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL13804206 | 0.90 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968716-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110003824-A1 | Caspase Inhibitors and Uses Thereof | VERTEX PHARMACEUTICALS INCORPORDTED (US) | 2011-01-06 | — | — | US | disclosed |
| US-7829561-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090023739-A1 | interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1289993-B9 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7407964-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1289993-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1289993-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020045623-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-18 | — | — | US | disclosed |
| WO-2001094351-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023739-A1 | interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis | IL1B, IL1RN, CASP1 | HSD17B10 325/4885SMN1; SMN2 3744/4885NPC1 3835/4885 |
| US-20020045623-A1 | Caspase inhibitors and uses thereof | CASP3, CASP1, CASP2 | HSD17B10 463/4885SMN1; SMN2 2842/4885NPC1 654/4885 |
| US-20110003824-A1 | Caspase Inhibitors and Uses Thereof | CASP3, CASP2, CASP1 | HSD17B10 443/4885SMN1; SMN2 3339/4885NPC1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.